FAMILIAL DYSAUTONOMIA NOW FOUNDATION

FD NOW is a 501c3 non-profit organization dedicated to funding the fast-track research at the Laboratory for Familial Dysautonomia Research at Fordham University in New York, USA.

THE CLINIC FOR SPECIAL CHILDREN INC

A nonprofit comprehensive medical practice focused on treating & researching rare genetic disorders.

• Birth Defects, Genetic Diseases

• 48.

International Rett Syndrome Association, Inc.

We are transforming lives every day in our fight to treat and cure Rett syndrome and better the lives of families living with this devastating disorder.

• Research Institutes and/or Public Policy Analysis

• 49.

Riaan Research Initiative Inc

501(c)(3) non-profit organization hunting for a cure for rare and life-limiting genetic diseases that hurt children, starting with Cockayne syndrome.

• Health - General & Rehabilitative N.E.C.

• 50.

Hereditary Neurological Disease Centre Inc

Official Twitter for Genentech. See our community guidelines here: https://t.

• Birth Defects, Genetic Diseases Research

• 51.

International FOXP1 Foundation

Our mission is to build a global community that empowers and supports families and individuals with FOXP1 syndrome by sharing knowledge, inspiring hope, supporting research, and raising awareness.

Lightning and Love Foundation

Founder of Lightning and Love foundation and mom to two ultra-rare THAP12 genetic epilepsy disease daughters searching for a cure.

• Fund Raising and/or Fund Distribution

• 53.

CURE RARE DISEASE INC

Nonprofit biotech leading a global collaboration to develop life-saving medicines for rare diseases Revolutionizing UltraRare Disease Treatment through Innovation and Collaboration Revolutionizing UltraRare Disease Treatment through Innovation and Collaboration What Wex27re Working Towards We envision a future where every patient has access to treatment.

• Fund Raising and/or Fund Distribution

• 54.

TO CURE A ROSE FOUNDATION

At To Cure A Rose Foundation, we’re on a mission to make genetic treatments faster, more affordable, and within reach—so that the next child born with a rare disease can receive a customized drug within days of diagnosis.